The estimated Net Worth of Asset Management, Lp Chen B... is at least $90.8 Миллион dollars as of 31 October 2018. Asset B owns over 133,333 units of Axonics Inc stock worth over $88,374,890 and over the last 8 years Asset sold AXNX stock worth over $2,459,652.
Asset has made over 11 trades of the Axonics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Asset bought 133,333 units of AXNX stock worth $1,999,995 on 31 October 2018.
The largest trade Asset's ever made was selling 504,027 units of Axonics Inc stock on 14 December 2017 worth over $2,459,652. On average, Asset trades about 211,839 units every 66 days since 2016. As of 31 October 2018 Asset still owns at least 1,285,827 units of Axonics Inc stock.
You can see the complete history of Asset B stock trades at the bottom of the page.
Over the last 6 years, insiders at Axonics Inc have traded over $108,010,643 worth of Axonics Inc stock and bought 4,672,163 units worth $70,180,620 . The most active insiders traders include Asset Management, Lp Chen B..., Shahzad Malik и Geoff Pardo. On average, Axonics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $4,280,711. The most recent stock trade was executed by Raymond W Cohen on 24 July 2024, trading 103,896 units of AXNX stock currently worth $2,383,374.
axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.
Axonics Inc executives and other stock owners filed with the SEC include: